Vol. 18/No. 02 | OncologyLive

BTK Inhibitors Mushroom in Blood Cancer Field

January 20, 2017

It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.

Veliparib Facing Phase III Test in BRCA-Positive Breast Cancer

January 12, 2017

Researchers are seeking to determine whether adding the PARP inhibitor veliparib to a chemotherapy combination will improve outcomes for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.

Challenges Persist in Deploying ADT in Prostate Cancer

January 11, 2017

In 1941, Charles Brenton Huggins, MD, observed that prostate cancer could be controlled by hormone-directed treatments, a discovery for which he was awarded half the Nobel Prize in Physiology or Medicine in 1966.

When Values Collide: The Individual Versus the Common Good

January 09, 2017

It is perhaps a little unusual that an oncol­ogy commentary would begin with a highly provocative discussion about the future of driverless cars, but there are similarities in the sharp corners of the debate over this new tech­nology and emerging trends in cancer care.